Product Review - Cladribine in the treatment of relapsing Multiple Sclerosis

This review discusses pathogenesis of MS and current treatments, implications of COVID-19 and evidence in support of the use of Cladribine, its pharmacological properties, dosage and administration, and efficacy and tolerability as demonstrated in pivotal clinical trials.

It also provides commentary and recommendations from Associate Professor Anneke van der Walt, a Neurologist and Head of MS and Neuro-immunology Unit and Neuro-ophthalmology Service at Alfred Health, Melbourne.

Please login below to download this issue (PDF)